Ipamorelin 10mg | NeuroPept Labs

Description

Ipamorelin is a synthetic pentapeptide and highly selective growth hormone secretagogue receptor (GHS-R1a) agonist studied extensively in neuroendocrine and metabolic research. Unlike broader-spectrum growth hormone-releasing peptides (GHRPs), Ipamorelin is characterised by its targeted receptor selectivity stimulating growth hormone (GH) release from the anterior pituitary without significantly engaging other pituitary hormone pathways such as ACTH or prolactin. This pharmacological profile makes it one of the most studied selective GHRPs in current preclinical research.

NeuroPept Labs supplies Ipamorelin 10mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are synthesised under controlled conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

Ipamorelin exerts its primary biological effects through high-affinity, selective binding to the GHS-R1a receptor the ghrelin receptor subtype expressed in the anterior pituitary and hypothalamus. Upon receptor activation, downstream cAMP and calcium signalling cascades are engaged, stimulating pulsatile growth hormone secretion from somatotroph cells.

Key mechanistic properties studied in research models include:

• Selective GHS-R1a agonism high binding affinity and specificity for the ghrelin receptor subtype, with minimal cross-reactivity to ACTH, cortisol, or prolactin pathways
• Pulsatile GH release stimulates acute, physiologically-patterned pulses of GH rather than sustained elevation, mimicking endogenous secretion rhythms
• Hypothalamic-pituitary axis modulation engages neuroendocrine feedback loops at both pituitary and hypothalamic GHS-R1a sites
• IGF-1 downstream signalling GH release triggered by Ipamorelin is studied for its downstream effects on hepatic IGF-1 production and anabolic signalling cascades
• Half-life (~2 hours) substantially longer than endogenous GHRH (~11-12 minutes), enabling more sustained but controlled receptor engagement in research protocols

Ipamorelin is frequently studied in combination with CJC-1295 No DAC  a GHRH receptor agonist as the two peptides act on complementary receptor pathways, enabling researchers to study additive or synergistic effects on GH axis signalling.

Research Applications

Current laboratory and preclinical investigation using Ipamorelin spans multiple research domains:

• Neuroendocrinology  hypothalamic-pituitary-somatotropic axis regulation and GHS-R1a receptor pharmacology
• Metabolic research  GH-mediated effects on glucose metabolism, lipolysis, and lean tissue signalling
• Ageing and longevity models  studying GH secretory decline associated with ageing and potential restoration pathways
• Bone metabolism research  GH/IGF-1 axis effects on osteoblast activity and bone mineral density in preclinical models
• Sleep and circadian biology  GH pulse architecture and its relationship to slow-wave sleep phases
• Combination peptide pharmacology dual-pathway GH axis stimulation studies using Ipamorelin + GHRH analogues

Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles to preserve structural integrity
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using appropriate sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended research timeframes

Frequently Asked Questions

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively binds to the GHS-R1a (ghrelin) receptor in the anterior pituitary and hypothalamus, stimulating pulsatile growth hormone release. It is distinguished by its high receptor selectivity and minimal interaction with other pituitary hormone pathways such as ACTH or prolactin.

How does Ipamorelin differ from other GHRPs?

Unlike GHRP-2 or GHRP-6, which engage broader receptor profiles and may elevate cortisol or prolactin in research models, Ipamorelin demonstrates a highly selective agonism specifically at GHS-R1a. This selectivity makes it a preferred tool for research requiring isolated GH axis stimulation without confounding hormonal effects.

Is Ipamorelin often studied with CJC-1295?

Yes. Ipamorelin (GHS-R1a agonist) and CJC-1295 No DAC (GHRH receptor agonist) act on complementary receptor pathways. Research protocols frequently combine both peptides to study additive or synergistic effects on pulsatile GH secretion through dual-pathway stimulation of the hypothalamic-pituitary somatotropic axis.

What purity is NeuroPept Labs’ Ipamorelin 10mg?

Our Ipamorelin 10mg research peptide is supplied at 98% purity, verified by HPLC and third-party analytical testing. Full COA documentation is available for every batch and can be verified at freedomdiagnosticstesting.com.

Scientific References

1. Growth Hormone-Releasing Peptides: Investigation of Their Receptor Interactions | PMC/NIH 2026
2. Sermorelin and Ipamorelin Potential in GH Regulation | BiotechPeptides 2025
3. Prolonged Stimulation of GH and IGF-1 by CJC-1295 | PubMed 2006

Research Use Disclaimer: All products sold by NeuroPept Labs are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. Purchasers are responsible for compliance with applicable regulations in their jurisdiction.